Brainsway (NASDAQ:BWAY – Get Free Report) issued its quarterly earnings data on Wednesday. The company reported $0.07 earnings per share for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03), FiscalAI reports. The company had revenue of $17.11 million for the quarter, compared to the consensus estimate of $16.54 million. Brainsway had a net margin of 15.65% and a return on equity of 13.01%.
Brainsway Stock Performance
NASDAQ BWAY traded down $0.27 on Friday, reaching $16.20. 13,566 shares of the company’s stock traded hands, compared to its average volume of 165,274. Brainsway has a fifty-two week low of $6.26 and a fifty-two week high of $17.40. The firm has a market cap of $650.31 million, a price-to-earnings ratio of 36.72 and a beta of 1.24. The stock has a 50 day moving average price of $15.13 and a 200-day moving average price of $14.36.
Institutional Trading of Brainsway
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. ARK Investment Management LLC purchased a new position in shares of Brainsway during the 4th quarter valued at approximately $2,422,000. Two Sigma Investments LP boosted its holdings in Brainsway by 25.2% during the third quarter. Two Sigma Investments LP now owns 102,902 shares of the company’s stock worth $1,551,000 after buying an additional 20,706 shares in the last quarter. UBS Group AG boosted its holdings in Brainsway by 2,028.6% during the third quarter. UBS Group AG now owns 63,878 shares of the company’s stock worth $963,000 after buying an additional 60,877 shares in the last quarter. Millennium Management LLC grew its position in Brainsway by 69.6% during the third quarter. Millennium Management LLC now owns 39,841 shares of the company’s stock valued at $600,000 after buying an additional 16,354 shares during the period. Finally, NewEdge Advisors LLC grew its position in shares of Brainsway by 7.4% during the 3rd quarter. NewEdge Advisors LLC now owns 28,629 shares of the company’s stock valued at $431,000 after acquiring an additional 1,964 shares during the period. 30.11% of the stock is owned by institutional investors and hedge funds.
Key Headlines Impacting Brainsway
- Positive Sentiment: BTIG raised its price target to $20 and reiterated a Buy rating, implying meaningful upside from recent trading levels. The firm’s bullish outlook helped trigger a sharp advance in BWAY shares. BTIG Research Forecasts Strong Price Appreciation for Brainsway Stock
- Positive Sentiment: Ladenburg Thalmann raised its price target from $18 to $18.80 and assigned a Buy rating, adding to the positive analyst momentum around the stock. Ladenburg Thalmann price target update
- Positive Sentiment: BWAY reached a new 52-week high following its quarterly results, indicating that investors responded favorably to the company’s operating performance and outlook. Brainsway Sets New 1-Year High Following Strong Earnings
- Neutral Sentiment: Second-quarter revenue was $17.11 million, above the $16.54 million consensus estimate, while earnings per share of $0.07 missed expectations of $0.10. The mixed results provide both evidence of demand growth and a reason for some profit-taking. BrainsWay Q2 2026 Earnings Call Transcript
- Negative Sentiment: Zacks Research downgraded BrainsWay from Strong Buy to Hold, creating a counterweight to the more bullish price-target increases and potentially contributing to the recent retreat from the high. Zacks Research rating update
Wall Street Analyst Weigh In
Several equities research analysts have weighed in on the stock. LADENBURG THALM/SH SH raised their target price on shares of Brainsway from $18.00 to $18.80 and gave the company a “buy” rating in a research note on Thursday. Weiss Ratings reiterated a “buy (b-)” rating on shares of Brainsway in a research note on Tuesday, July 21st. BTIG Research boosted their price target on Brainsway from $18.00 to $20.00 and gave the stock a “buy” rating in a research note on Wednesday. Wall Street Zen upgraded shares of Brainsway from a “hold” rating to a “buy” rating in a report on Sunday, August 2nd. Finally, Zacks Research cut shares of Brainsway from a “strong-buy” rating to a “hold” rating in a research note on Tuesday. Six equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat.com, Brainsway has an average rating of “Moderate Buy” and an average price target of $16.95.
Read Our Latest Research Report on BWAY
About Brainsway
Brainsway Ltd is a medical device company specializing in non-invasive neuromodulation therapies. Publicly traded on the NASDAQ under the symbol BWAY, the company develops and commercializes deep transcranial magnetic stimulation (Deep TMS) systems designed to treat a range of neuropsychiatric and neurological disorders. Brainsway’s technology aims to offer an alternative or complement to traditional pharmacological therapies by targeting precise brain regions with its patented coil designs.
The company’s flagship Deep TMS platform utilizes proprietary H-coil arrays engineered to reach deeper cortical structures than conventional TMS devices.
Featured Articles
- Five stocks we like better than Brainsway
- Joint Operations: Curaleaf Makes a Play for Aurora Cannabis
- Cerebras Sells Off After Earnings: Is This a Market Disconnection?
- Is Lockheed Martin Gearing Up to Lead Defense Stocks?
- Inside Teledyne’s Bold Bet on the Future of Medical Imaging
Receive News & Ratings for Brainsway Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainsway and related companies with MarketBeat.com's FREE daily email newsletter.
